Karolinska Development AB represents a value-driven corporate philosophy focused on enabling the commercialization of innovative life science technologies. The company is dedicated to improving human health and actively supports the development of breakthrough therapies and medical innovations. Karolinska Development AB strives for long-term financial success while prioritizing ethical and sustainable practices. By identifying promising projects and providing strategic guidance, funding, and industry expertise, the company accelerates the growth of healthcare companies and fosters collaborations within the life science sector. Karolinska Development AB's commitment to driving scientific advancements and delivering shareholder value positions it as a leading player in the industry.

Karolinska Development AB, a renowned Swedish life science investment company, primarily operates in Sweden. With its headquarters situated in Stockholm, the company focuses on identifying and developing innovations within the healthcare sector. Karolinska Development AB plays a crucial role in supporting the commercialization and growth of early-stage life science companies originating from Sweden's prestigious Karolinska Institutet. With an extensive network of contacts and partnerships, Karolinska Development AB drives advancements in the field of biomedicine, primarily within Sweden's vibrant life science ecosystem.

Karolinska Development AB, a leading Nordic life science investment company, has achieved several significant milestones. The company has successfully supported the growth of numerous innovative healthcare companies and fostered collaborations with top academic institutions. Karolinska Development has enabled the development and commercialization of several breakthrough therapies and medical technologies, addressing critical unmet medical needs. Its extensive portfolio encompasses companies focusing on various therapeutic areas, including oncology, rare diseases, and regenerative medicine. With its strategic investments and valuable expertise, Karolinska Development continues to play a vital role in advancing the life sciences industry and improving patient outcomes.

Karolinska Development AB is a leading investment company in the field of life sciences. Established in 2003, the company focuses on identifying and developing innovative pharmaceutical products and medical technologies. As a subsidiary of Karolinska Institutet Holding AB, Karolinska Development collaborates with academia, top-notch experts, and industry stakeholders to bring promising research and commercialize breakthrough innovations. The company's portfolio includes a diverse range of investments in companies involved in drug development, medical devices, diagnostics, and digital health solutions. Karolinska Development aims to leverage its extensive network and knowledge to drive the growth and success of its portfolio companies in the global healthcare market.

The main competitors of Karolinska Development AB in the market include other biotechnology and pharmaceutical companies focusing on innovation and drug development. Some notable competitors include AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, and Johnson & Johnson. These companies compete in the same industry, striving to bring new drugs and therapies to the market. Karolinska Development AB sets itself apart through its expertise in evaluating and identifying promising early-stage life science opportunities.

Karolinska Development AB is primarily active in the life sciences and healthcare industries.

Karolinska Development AB operates as a life sciences investment company. The company's business model focuses on identifying, developing, and commercializing innovative healthcare technologies originating from leading academic research institutions in the Nordic region. Karolinska Development AB aims to support the growth of these projects by providing expertise, funding, and strategic guidance. By actively participating in the development process, the company strives to maximize the potential value of its portfolio of companies. Through partnerships and collaborations, Karolinska Development AB aims to advance medical innovations that address significant unmet medical needs, ultimately benefiting both patients and investors.

De Karolinska Development K/W is -11,94.

De Karolinska Development KUV is 159,52.

De AlleAktien Qualitätsscore kan momenteel niet berekend worden voor Karolinska Development.

De verwachte Karolinska Development omzet is 2,04 mln. SEK.

De verwachte Karolinska Development winst is -27,26 mln. SEK.

Karolinska Development AB specializes in the development of medications and medical technologies. The company's business model is based on building partnerships with promising startups and research institutions in the healthcare sector and supporting them in bringing their products and technologies to market. The company operates in four strategic business areas: company formation, technology development, product development, and management consulting. Karolinska Development AB aims to become a leading company in the healthcare industry and promote the development of medications and medical technologies.

Karolinska Development keert een dividend van 0 SEK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Karolinska Development of het bedrijf keert geen dividend uit.

De ISIN van Karolinska Development is SE0002190926.

Het WKN van Karolinska Development is A0M84G.

De ticker van Karolinska Development is KDEV.ST.

Binnen de laatste 12 maanden betaalde Karolinska Development een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Karolinska Development naar verwachting een dividend van 0 SEK betalen.

De dividendrendement van Karolinska Development is momenteel .

Karolinska Development betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Karolinska Development betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 SEK verwacht. Dit komt overeen met een dividendrendement van 0 %.

Karolinska Development wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Karolinska Development van 2-11-2024 ter hoogte van 0 SEK te ontvangen, moest je het aandeel voor de ex-datum op 2-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 2-11-2024.

In het jaar 2023 heeft Karolinska Development 0 SEK aan dividenden uitgekeerd.

De dividenden van Karolinska Development worden in SEK uitgekeerd.